Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 open-label dose-ranging study of PBKR03 in early infantile Krabbe disease
MOH_2021-12-19_010490Phase 2Completed
- Sponsor
- Passage Bio
- Start
- May 2021
- Modality
- Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of PBKR03 in Krabbe disease (5 arms), sponsored by Passage Bio. Primary endpoint: Safety and tolerability of PBKR03. Started May 2021; status: completed.
02
Drugs
PBKR03
03
Conditions
Krabbe disease
Beyond the preview
Go deeper on MOH_2021-12-19_010490.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-12-19_010490.